Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
Starting with a liver-tropic lead from 90 degradable lipidoids, researchers attached small-molecule ligands to redirect delivery toward the lung. The modified particles showed increased vitronectin association and enhanced pulmonary mRNA expression, with genome-editing proof of concept. This modular chemical approach retains the parent scaffold, but its targeting performance remains demonstrated in preclinical experimental conditions.
Vilya’s technical preprint describes an all-atom model for conformational sampling and developability prediction across macrocycles with diverse chemistries and noncanonical residues. The framework supports permeability modeling and molecular design within the company’s oral-macrocycle strategy. Computational benchmark performance does not demonstrate human oral bioavailability, efficacy, or safety; the report is a preprint rather than peer-reviewed clinical evidence.
Salubris announced NMPA clinical-trial clearance for SAL0167 tablets for hyperlipidemia and identified the proprietary candidate as a cyclic peptide. The authorization permits clinical development but does not establish human dosing, quantitative oral exposure, or lipid-lowering efficacy. General statements about cyclic-peptide advantages should not be treated as demonstrated properties of this particular candidate.
GEMMABio announced ARPA-H funding for RAPID, a collaboration with Profluent under the THRIVE program. The project aims to develop four LNP-delivered, mRNA-encoded base-editing products for selected founder mutations causing homozygous familial hypercholesterolemia or maple syrup urine disease. The release did not disclose an award amount. Editor selection and delivery development remain research objectives, rather than demonstrated patient benefit.
Researchers designed a pulmonary mRNA-LNP vaccine that combines early innate immune activation with later antigen-specific protection. Intratracheal vaccination primed neutrophils and macrophages and subsequently generated adaptive responses against Pseudomonas aeruginosa, including drug-resistant isolates. Single-cell profiling supported a coordinated immune mechanism. The protection experiments were conducted in female mice, rather than patients.
An ionizable-lipid screening campaign produced an LNP formulation for dendritic-cell mRNA delivery. Researchers coencapsulated tumor-antigen mRNA, cyclic di-AMP, and manganese to coordinate antigen production with STING activation. The combination enhanced antigen presentation, tumor-specific T-cell responses, and antitumor activity in experimental models. It is a preclinical platform, with no demonstrated patient benefit in this report.
This study developed biologically assembled RNA delivery particles, termed RNA-BEVs, for topical skin applications. The vectors transferred functional mRNA into keratinocytes and reconstructed epidermis, enabling transient protein production. In diabetic rats, wound repair histology improved relative to the tested mRNA-LNP comparator. These biologically engineered vectors are a distinct carrier class, rather than conventional lipid nanoparticles.
Certara launched Bio Venture Catalyst, bringing together scientific development, regulatory, commercial, and investor-oriented strategy. The announcement includes model-informed development support and asset prioritization. The offering is a consulting service; its stated aims do not demonstrate improved clinical outcomes or guarantee financing.
LG AI Research and D&D Pharmatech signed a master agreement for next-generation oral peptide discovery, explicitly including macrocyclic peptides. The collaboration combines AI design with peptide development expertise. Named candidates, targets, financial terms, and human results were not disclosed. The agreement sets research objectives rather than demonstrating that oral absorption or clinical efficacy challenges have been solved.
Ironwood announced FDA approval of linaclotide for functional constipation in children ages 2 and older, extending the previous indication covering ages 6 and older. A 12-week, placebo-controlled Phase 3 trial in children ages 2–5 supported the decision, with improved spontaneous bowel-movement frequency at 72 micrograms. This concerns a gut-acting oral peptide, rather than systemic peptide delivery.
This perspective examines digital-twin claims against established pharmacometric practice. It argues that individual simulation, sequential updating, and decision-focused uncertainty analysis have longstanding roots in PK/PD modeling. The author emphasizes that fundamental limits, including identifiability, remain relevant despite new terminology.
20n Bio announced $7.5 million in Seed+ financing to advance AI-enabled cyclic peptide discovery, screening workflows, and its therapeutic pipeline. The company identifies oral peptides among potential applications but has not disclosed a validated clinical oral cyclic peptide candidate or human oral pharmacokinetics. The strategic lead investor was unnamed; investors from earlier rounds should not be assigned to this financing.
